MAP
TGTX icon

Moody Aldrich Partners’s TG Therapeutics TGTX Stock Holding History

Moody Aldrich Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-77,278
Closed -$1.92M – 214
2023
Q2 		$1.92M Buy
+77,278
New +$2M 0.37% 96
2023
Q1 		– Sell
-103,925
Closed -$1.23M – 177
2022
Q4 		$1.23M Buy
+103,925
New +$754K 0.25% 112
2021
Q3 		– Sell
-74,599
Closed -$2.89M – 183
2021
Q2 		$2.89M Sell
74,599
-909
-1% -$35.7K 0.41% 88
2021
Q1 		$3.64M Buy
75,508
+1,248
+2% +$60K 0.52% 75
2020
Q4 		$3.86M Buy
+74,260
New +$2.51M 0.62% 75

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moody Aldrich Partners's TGTX Position: Q3 2023 in Review

Moody Aldrich Partners sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 77,278 shares — an estimated $1.92M sold.

Moody Aldrich Partners first reported a position in TGTX in Q4 2020 and held it in 5 quarters. The position peaked at $3.86M in Q4 2020. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Moody Aldrich Partners reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 77,278 TG Therapeutics shares in Q3 2023, an estimated $1.92M.
  • Moody Aldrich Partners first reported a position in TG Therapeutics in Q4 2020 and held it in 5 quarters.
  • Moody Aldrich Partners's TG Therapeutics position peaked at $3.86M in Q4 2020.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Moody Aldrich Partners's 13F filing for Q3 2023, filed 8 Nov 2023.